BioSpace News Archive

Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people.

Athletico Physical Therapy waives Co-payments and Co-insurance for First Responders and Licensed Health Care Professionals Diagnosed with COVID-19

For the nascent brain of a human embryo to develop into the complex organ that controls human consciousness, a finely tuned sequence of genetic events has to take place; hundreds of genes are activated and deactivated in a precise symphony.

TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has commenced an underwritten offering of common stock.

Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications.

Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced that it has commenced an underwritten public offering of its common stock,

Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors.

Lipidor AB (“Lipidor” or the “Company”) and its subsidiary Emollivet AB (“Emollivet”) have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor’s patented AKVANO® technology

Synergy CHC Corp (OTCM: SNYR) (the “Company”), a consumer healthcare company, intends to file a Form 15 with the SEC to voluntarily effect the deregistration of its Common Stock.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), has been added to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), and the listing will take effect on July 16.